{
  "source": "PA-Notification-Cotellic.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1175-10\nProgram Prior Authorization/Notification\nMedication Cotellic® (cobimetinib)\nP&T Approval Date 1/2016, 12/2016, 11/2017, 11/2018, 11/2019, 11/2020, 11/2021,\n11/2022, 11/2023, 11/2024\nEffective Date 2/15/2025\n1. Background:\nCotellic (cobimetinib) is a kinase inhibitor indicated for the treatment of patients with\nunresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination\nwith Zelboraf® (vemurafenib) and as a single agent for the treatment of patients with histiocytic\nneoplasms.1 The National Cancer Comprehensive Network (NCCN) also recommends the use of\nCotellic in combination with Zelboraf® (vemurafenib) as treatment for Central Nervous System\n(CNS) Cancers.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Cotellic will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Melanoma\n1. Initial Authorization\na. Cotellic will be approved based on all of the following criteria:\n(1) Diagnosis of melanoma\n-AND-\n(2) One of the following:\n© 2024 UnitedHealthcare Services, Inc.\n1\n(a) Patient has unacceptable toxicities to Tafinlar (dabrafenib) or Mekinist\n(trametinib) on the basis of agent side-effect profile\n-OR-\n(b) Disease is one of the following:\ni. Relapsed > 3 months after treatment discontinuation\nii. Unresectable\niii. Metastatic\n-AND-\n(3) Disease is positive for one of the following mutati",
    " profile\n-OR-\n(b) Disease is one of the following:\ni. Relapsed > 3 months after treatment discontinuation\nii. Unresectable\niii. Metastatic\n-AND-\n(3) Disease is positive for one of the following mutations:\n(a) BRAF V600E\n(b) BRAF V600K\n-AND-\n(4) Used in combination with Zelboraf (vemurafenib)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cotellic will be approved based on both of the following criteria:\n(1) Patient does not show evidence of progressive disease while on Cotellic therapy\n-AND-\n(2) Used in combination with Zelboraf (vemurafenib)\nAuthorization will be issued for 12 months.\nC. Central Nervous System (CNS) Cancers\n1. Initial Authorization\na. Cotellic will be approved based on all of the following criteria:\n(1) Diagnosis of one of the following:\n(a) Circumscribed glioma\n(b) Glioblastoma\n(c) Limited brain metastases\n© 2024 UnitedHealthcare Services, Inc.\n2\n(d) Extensive brain metastases\n-AND-\n(2) Disease is BRAF V600E positive\n-AND-\n(3) Used in combination with Zelboraf (vemurafenib)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cotellic will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Cotellic therapy\n-AND-\n(2) Used in combination with Zelboraf (vemurafenib)\nAuthorization will be issued for 12 months.\nD. Histiocytic Neoplasms\n1. Initial Authorization\na. Cotellic will be approved based on the following criterion:\n(1) Diagnosis of one of the following histiocytic neoplasms:\n(a) Langerhans cell histiocytosis\n(b) Erdheim-Chester disease\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cotellic will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Cotellic\ntherapy.\nAuthorization will be issued for 12 months.\nE. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics C",
    "will be issued for 12 months.\nE. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\n© 2024 UnitedHealthcare Services, Inc.\n3\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Cotellic [package insert]. Genentech USA, Inc.: South San Francisco, CA; May 2023.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org. Accessed September 25, 2024.\nProgram Prior Authorization/Notification – Cotellic (cobimetinib)\nChange Control\n1/2016 New program.\n12/2016 Annual Review. Added criteria to use in combination with Zelboraf.\nUpdated references.\n11/2017 Annual Review. Updated references.\n11/2018 Annual review. Added coverage for CNS cancers per NCCN\nguidelines. Updated background and references.\n11/2019 Annual review. Added in combination with Zelboraf (vemurafenib) to\ncontinuation therapy. Added NCCN recommended regimens criteria.\nUpdated references.\n11/2020 Annual review. Updated background to match coverage criteria. No\nchange in coverage criteria. Updated references.\n11/2021 Annual review. Updates per NCCN recommendations to CNS cancer\nand histiocytic neoplasms. Updated reference.\n11/2022 Annual review. Updated CNS cancer criteria removing BRAF V600K\nto align with NCCN recommendations. Added sta",
    "er NCCN recommendations to CNS cancer\nand histiocytic neoplasms. Updated reference.\n11/2022 Annual review. Updated CNS cancer criteria removing BRAF V600K\nto align with NCCN recommendations. Added state mandate footnote.\nUpdated references.\n11/2023 Annual review. Updated histiocytic neoplasms criteria based on labeled\nindication and CNS cancer based on NCCN recommendations.\nUpdated background and references.\n11/2024 Annual review. Updated melanoma, central nervous system cancers,\n© 2024 UnitedHealthcare Services, Inc.\n4\nand histiocytic neoplasms criteria based on NCCN guidelines.\n© 2024 UnitedHealthcare Services, Inc.\n5"
  ]
}